Next Article in Journal
BP1003 Decreases STAT3 Expression and Its Pro-Tumorigenic Functions in Solid Tumors and the Tumor Microenvironment
Previous Article in Journal
Gas Chromatography–Mass Spectrometry-Based Analyses of Fecal Short-Chain Fatty Acids (SCFAs): A Summary Review and Own Experience
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Biomedicines
Volume 12
Issue 8
10.3390/biomedicines12081902
biomedicines-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Impact of Urethral Sphincter Electrophysiology on Botulinum Toxin A Treatment in Women with Non-Neurogenic Dysfunctional Voiding

by
Tien-Lin Chang
,
Yuan-Hong Jiang
and
Hann-Chorng Kuo
*
Department of Urology, Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation and Tzu Chi University, Hualien 970, Taiwan
*
Author to whom correspondence should be addressed.
Biomedicines 2024, 12(8), 1902; https://doi.org/10.3390/biomedicines12081902
Submission received: 8 July 2024 / Revised: 9 August 2024 / Accepted: 14 August 2024 / Published: 20 August 2024
(This article belongs to the Section Molecular and Translational Medicine)
Browse Figure
Review Reports Versions Notes

Abstract

:
Dysfunctional voiding (DV) is an abnormal urethral sphincter activity during voiding in neurologically normal individuals. Urethral sphincter botulinum toxin A (BoNT-A) injection has been used to treat DV, but the results have not been completely satisfactory. This study investigated the neurological characteristics of women with DV using the lower urinary tract electrophysiology (EP) study and the therapeutic efficacy of BoNT-A injection. In total, 48 women with DV and 16 women with normal voiding were included. Videourodynamic studies were conducted to diagnose DV before BoNT-A injection. EP studies, including urethral sphincter electromyography, bulbocavernosus reflex, and pudendal nerve conduction velocity, were conducted. Polyphasic motor unit action potentials suggestive of reinnervation were detected in 58.3% of patients with DV and 18.8% of controls (p = 0.001). Significant improvement in the corrected maximum flow rate (cQmax) was observed in patients with reinnervation at 1 and 3 months after BoNT-A injections into the urethral sphincter. Urethral sphincter denervation or reinnervation activity was commonly noted in 62.5% of women with DV. Repeated BoNT-A injections into the urethral sphincter provided effective treatment in 47.9% of patients, with mild improvement in cQmax observed in patients with urethral sphincter reinnervation. However, the improvement was not superior to those without reinnervation.

1. Introduction

Dysfunctional voiding (DV) is an abnormality of bladder emptying in neurologically normal individuals with increased external sphincter activity during voluntary voiding, causing functional bladder outlet obstruction (BOO). DV can cause various lower urinary tract symptoms, including storage and emptying symptoms. DV is the most common form of voiding dysfunction in women with clinically unsuspected BOO [1]. Furthermore, it can cause recurrent urinary tract infections, acute or chronic urinary retention, and, in severe cases, upper and lower urinary tract decompensation [2]. Accurate diagnosis of DV is essential for selecting appropriate treatment. Videourodynamic studies (VUDS) can provide an accurate diagnosis of DV. The VUDS of DV is characterized by increased external sphincter activity during voiding, high voiding detrusor pressure (Pdet), low maximum flow rate (Qmax), and increased post-void residual (PVR) volume, as well as a typical downward spiral shape in voiding cystourethrography [3]. DV is often encountered in adult women. In a retrospective analysis of VUDS in 1914 women with voiding dysfunction, DV was detected in 325 (17%), and poor relaxation of the urethral sphincter was observed in 336 women (17.6%) [3]. Adult women with lower urinary tract symptoms may have a high prevalence of DV history during childhood [4].
Effective treatments for DV include biofeedback pelvic floor muscle exercises, antimuscarinic therapy, sacral neuromodulation, and posterior tibial nerve stimulation [5,6,7,8]. Since no definitive treatment has been reported for DV, external urethral sphincter (EUS) botulinum toxin A (BoNT-A) injection has been used to relax the EUS [9]. However, not all patients with DV have satisfactory treatment outcomes after BoNT-A injection [10]. Although enthusiastic bladder management has been provided to patients with DV, many still cannot resume normal micturition and clean intermittent catheterization is needed [11]. These unsuccessful treatment outcomes for DV may be due to an inadequate understanding of the underlying pathophysiology, such as detrusor dysfunction, urethral sphincter or pelvic floor dysfunction, or abnormal micturition reflex regulation [12]. Therefore, meticulous neurologic and urodynamic examinations are necessary to determine possible electrophysiological pathophysiology and appropriately select patients with specific DV subtypes for medical or surgical treatment. Thus, this study aimed to investigate the neurological characteristics of patients with DV using the lower urinary tract electrophysiology (EP) study and the therapeutic efficacy of BoNT-A injection into the urethral sphincter for DV. Based on the results of this study, we might have evidence to select appropriate patients with DV and certain EP characteristics for BoNT-A injection into the urethral sphincter.

2. Materials and Methods

A total of 48 women diagnosed with VUDS-confirmed DV at the department of urology of a single medical center between November 2020 and April 2023 were enrolled in this study. Women with DV were enrolled in this clinical trial for urethral BoNT-A treatment. Furthermore, 16 women without voiding dysfunction were enrolled as controls. Because this was a preliminary observational study, no power calculation was made in the study design. This study was approved by the Institutional Review Board of the hospital (approval number: 110-265-A). Informed consent was obtained from all patients.
All patients underwent VUDS for DV diagnosis. The VUDS procedure and reported parameters were in accordance with the recommendations of the International Continence Society [13]. In VUDS, DV is characterized by an intermittent and/or fluctuating flow rate due to involuntary intermittent contractions of the periurethral striated or levator muscles during voiding in neurologically normal women [14]. Patients with a voiding detrusor pressure >35 cmH2O, Qmax < 15 cmH2O, spinning top appearance of urethral narrowing during voiding in VUDS, and symptoms of lower urinary tract dysfunction, including severe difficult urination, large PVR volumes, and chronic urinary retention, were diagnosed with DV and included in this study [1,10]. Patients with a voiding detrusor pressure <35 cmH2O, those without a narrow urethra during voiding, those without non-neurogenic pelvic floor dysfunction, and those with overt neurogenic lower urinary tract dysfunction, such as intracranial lesions, spinal cord injury, myelomeningocele, multiple sclerosis, and transverse myelitis, were excluded from this study.
Patients underwent lower urinary tract EP studies, including the bulbocavernosus reflex (BCR) by electrical stimulation, nerve conduction velocity (NCV) study of the pudendal nerve, and concentric electromyography (EMG) study of the EUS using Medtronic Keypoint EP equipment [15]. EP studies were conducted before the first BoNT-A injection into the urethral sphincter, with intravenous sedation, with the patients placed in the dorsal lithotomy position. EP testing of the BCR was performed using external stimulation of the dorsal nerve of the clitoris, and signals were recorded using surface electrodes on the perianal striated sphincter muscle. Thus, an objective study of the sacral reflex arc (S2–S4) was conducted. The latency time in a normal BCR is approximately 33 ms, and prolongation of this interval is a sign of a pathological reflex. An NCV study of the pudendal nerve was performed using a St. Mark’s electrode to transrectally stimulate the bilateral pudendal nerves at the level of the ischial spine and to record the response at the external anal sphincter muscle [16]. The typical pudendal nerve terminal motor latency response in healthy individuals is approximately 2.5 ms with an amplitude of 1 mV. The concentric needle EMG study was conducted by inserting the EMG needle from the periurethral area. EMG is a diagnostic test to assess the neuromuscular function of muscles. The urethral sphincter muscles are tonically active and exhibit normal continuously firing motor unit action potentials (MUAPs) even at rest. For adequate analysis, at least 10 MUAPs should be recorded. Denervated muscle fibers may produce rhythmic spontaneous electric potentials, such as fibrillation and positive sharp waves, which are thought to be characteristic of denervation changes. The presence of polyphasic or giant MUAPs is a sign of reinnervation [17] (Figure 1). The urethral sphincter EMG study using a concentric needle has been widely used in detecting inadequate relaxation of the urethral sphincter in DV or predicting treatment outcome of sacral neuromodulation in patients with Fowler’s syndrome, with good reliability and validity [18,19].
BoNT-A injections into the urethral sphincter were performed in the operating room for all patients under intravenous general anesthesia. Patients were admitted to the hospital for a 100 U BoNT-A injection every 3 months, and the urethral sphincter BoNT-A injection was performed four times. BoNT-A injection was performed based on a previous study [9]. After BoNT-A injections, a 14-Fr Foley catheter was routinely placed overnight. Patients were monitored at the outpatient clinic 1, 3, 6, and 9 months after the fourth BoNT-A injection. Uroflowmetry, maximum flow rate (Qmax), PVR, corrected Qmax (cQmax, Qmax divided by the square root of voided volume plus PVR), voiding efficiency, and the global response assessment (GRA) questionnaire for assessing voiding difficulty (scored from −3 (markedly worse) to +3 (markedly improved)), and visual analog scale (VAS) for dysuria (scored from 0 (no dysuria) to 10 (severe dysuria)) was performed to evaluate the treatment outcomes of urethral sphincter BoNT-A injections. Patients with improvement in cQmax and GRA were considered to have a satisfactory response to urethral BoNT-A injections.
Continuous variables were presented as mean ± standard deviation, and the rate of abnormal EP findings was presented. Differences in EP study parameters between the two groups were analyzed using the chi-square test. All calculations were performed using SPSS for Windows, version 16.0 (SPSS). A p-value < 0.05 was considered significant.

3. Results

A total of 64 women, including 48 with DV and 16 controls, with mean ages of 55.2 ± 16.1 and 61.1 ± 14.7 years, respectively, were included in this study. The controls were women who had stress urinary incontinence without voiding difficulty and were ready for anti-incontinence surgery. Table 1 presents the baseline demographics and VUDS diagnosis of patients with DV. Of the 48 patients, 7 (14.6%) had undergone transurethral incision of the bladder neck (TUI-BN) for previously diagnosed bladder neck dysfunction, but DV was present after TUI-BN. Additionally, 10 (20.8%) patients had previous hysterectomy, and 4 (8.3%) had previous spinal surgery. Among the patients with DV, 38 (79.2%) had concomitant urodynamic detrusor overactivity (DO), 1 (2.1%) had detrusor underactivity (DU), and 2 had vesicoureteral reflux during the VUDS examination. Of the 16 controls, 4 (25%) had intrinsic sphincter deficiency, 2 (12.5%) had DU, and 3 (18.8%) had DO.
Table 2 presents the VUDS and EP study parameters of patients with DV and controls. In the VUDS, no significant differences were observed in Qmax, voided volume, PVR, cystometric bladder capacity, corrected Qmax (cQmax), voiding efficiency, or bladder contractility index. The voiding detrusor pressure was significantly higher in patients with DV than in controls. In the EP study, 60.4% of patients with DV and 87.5% of controls had a normal BCR latency time (p = 0.092). In the NCV study, decreased amplitude was observed in 75.0% of patients with DV and 56.2% of controls. In the EMG studies, only two patients with DV (4.2%) had positive sharp waves, indicating denervation, whereas the controls showed no positive sharp waves. Polyphasic MUAPs were observed in 58.3% of patients with DV who presented with reinnervation, whereas they were observed only in 18.8% of controls (p = 0.001).
The 48 women with DV were divided into two subgroups: those with reinnervation (n = 28) and those without reinnervation (including denervation and normal EMG subgroup, n = 20). Table 3 presents the VUDS and EP study parameters. There were no significant differences in the baseline VUDS and EP parameters between the two subgroups. However, after BoNT-A injections into the urethral sphincter, cQmax significantly increased at 1 and 3 months after BoNT-A treatment in patients with DV with reinnervation, whereas it did not increase in patients without reinnervation (Table 4). However, no significant differences in GRA results were observed between the two subgroups at 1, 3, 6, and 9 months after BoNT-A injections into the urethral sphincter. Of the 48 patients with DV, 23 (47.9%), including 13 (46.4%) and 10 (50.0%) with and without reinnervation, respectively, reported satisfactory treatment outcomes (GRA ≥ 2) after urethral sphincter BoNT-A injections (p = 0.503).
Table 5 presents the characteristics of patients with GRA ≥ 2 and GRA < 2 after BoNT-A injection into the urethral sphincter. No significant differences in VUDS and EP parameters were observed between the two subgroups. The VAS score for dysuria significantly improved at all time points after BoNT-A treatment in both subgroups. However, no significant difference in the improvement of the VAS score for dysuria was observed between the two groups.

4. Discussion

This study showed that 62.5% of women with a videourodynamic diagnosis of non-neurogenic DV and dysuria had neurological deficits in the urethral sphincter in the EP study. After repeated urethral sphincter BoNT-A injections, only 47.9% of patients with DV had satisfactory treatment outcomes. Patients with DV and reinnervation in the EP study showed a significant improvement in cQmax at 1 and 3 months after BoNT-A injection, and the therapeutic effect gradually declined. However, the changes in GRA and improvement in VAS score for dysuria were not significant compared with patients with DV without reinnervation.
The actual pathophysiology of DV has not been elucidated. DV might be associated with lower urinary tract neuropathy, including BCR reflex arc, pudendal neuropathy, and urethral sphincter neuropathy [17]. Potential neurological deficits should be considered before treatment. In our previous EP study, a high percentage of neurological deficiency was observed in patients with DU [15]. The BCR, pudendal NCV study and urethral sphincter EMG were used to assess lower urinary tract dysfunction and neuropathy. The BCR test is used to evaluate whether the conus medullaris and the S2–S4 pelvic nerves are intact. Testing for the absence of this reflex may indicate neurological deficits located at the pelvic nerves or cauda equina [16]. The pudendal NCV study tests pudendal nerve injury or other neuropathy. A prolonged latency time or lower nerve conduction velocity indicates possible nerve demyelination changes, whereas decreased amplitude in the pudendal NCV study indicates axonopathy [20]. The motor-unit EMG assesses the neuromuscular function of the urethral sphincter using concentric needle EMG [21]. Abnormal polyphasic high-amplitude MUAPs have been observed in female voiding dysfunction due to DV or Fowler’s syndrome [22]. The high rate of reinnervation observed in EMG studies of EUS indicates that urethral sphincter neuropathy occurs, and abnormally increased urethral sphincter activity is present in most patients with DV [23].
In this study, the absence of BCR, decreased amplitude in pudendal NCV studies, and changes in urethral sphincter reinnervation were detected in 39.6%, 75.0%, and 58.3% of patients with DV, respectively. All of the incidences of abnormal EP studies were higher in patients with DV than in the control group, even though only the reinnervation changes were statistically significant (p = 0.001). Reinnervation of the urethral sphincter indicates incomplete or inadequate recovery from previous neurological insults, which may result in a non-relaxing urethral sphincter (in denervation DV) or impaired relaxation of the urethral sphincter (in reinnervation DV) during voiding, leading to functional BOO and voiding difficulty [24]. Furthermore, the absence of BCR and decreased amplitude in the pudendal NCV indicates neuropathy of the micturition reflex arc or internal pudendal nerve.
DV is defined as the habitual contraction/hyperactivity of the urethral sphincter during voiding, resulting in high voiding pressure with a low Qmax and a spinning top appearance on voiding cystourethrography [25]. DV causes voiding symptoms, such as a slow stream and large PVR volume. Attempts to reduce hypertonicity or hyperactivity of the urethral sphincter with medication and resume spontaneous voiding usually result in treatment failure [11]. Psychological factors contributing to voiding dysfunction, such as anxiety and depression, have been suggested to cause low detrusor contractility and non-relaxing urethral sphincter by inhibiting detrusor contraction [26]. Although urethral sphincter BoNT-A injections can reduce urethral resistance, the decrease in urethral sphincter activity might not have a pharmacological effect on DV due to psychological insult [26].
Treatment options for DV in women and children include psychological support, medical therapy, biofeedback physiotherapy, urethral sphincter BoNT-A injection, sacral neuromodulation, and percutaneous tibial nerve stimulation [27,28]. Previous studies have reported a successful treatment outcome rate of 60%–100% in patients with DV, including pediatric and adult patients, after urethral sphincter BoNT-A injections [29,30,31]. Patients with successful treatment outcomes showed subjective improvement in dysuria and improvement in voiding pressure and PVR. In this study, patients with DV showed improved cQmax in the first and third months after urethral sphincter BoNT-A injections. Furthermore, VAS scores for dysuria improved in the first, third, sixth, and ninth months after BoNT-A treatment. These findings indicated that urethral sphincter BoNT-A injections reduced urethral resistance. However, the therapeutic effects were limited in patients with DV with reinnervation. Although the initial therapeutic effect might be satisfactory, the effect declined gradually with time. Therefore, repeated urethral sphincter BoNT-A injections are needed to maintain therapeutic efficacy.
The therapeutic mechanism of BoNT-A in striated or smooth muscle involves the inhibition of acetylcholine release from nerve terminals, resulting in the paralysis of part of the muscle cells [10,32]. After injecting BoNT-A into the urethral sphincter, it relaxes, and BoNT-A may be transported into the dorsal horn of the sacral cords, inhibiting the chronic inflammation that causes hyperactivity of the urethral sphincter and providing dual mechanisms of action that result in improving voiding condition [33]. However, only approximately half of patients with DV can have a good benefit from urethral sphincter BoNT-A injection [10,34,35]. Patients with acontractile detrusor and urinary retention could remove a catheter and reduce PVR after urethral BoNT-A injection [36]. An analysis of patients’ baseline characteristics revealed that patients with a higher baseline BOO index had a successful response to BoNT-A injection [35]. In women with a more severe form of DV, Fowler’s syndrome, the urethral BoNT-A injection improved symptoms after treatment [37]. This study showed that the characteristics of DV in VUDS, higher voiding pressure, and reinnervation EMG subtypes did not play a role in predicting successful treatment outcomes. The usual dose of BoNT-A injection for adult patients with DV is 100 U [9,10], which might be inadequate to paralyze the urethral sphincter or effective in inhibiting sacral cord inflammation. It is also possible that we do not fully understand the underlying pathophysiology of DV [38]. Other unknown pathophysiological factors underlying DV may also contribute to this unsatisfactory treatment outcome and warrant further investigation.
The pathophysiology of DV in neurologically normal women is not well elucidated. Although neurological deficits were observed in this study, the reason why BoNT-A injection could not effectively relax the urethral sphincter remains unknown. Our previous studies on urinary biomarkers in women with lower urinary tract dysfunction have shown that women with DV had higher urinary levels of tumor necrosis factor-alpha and 8-hydroxydeoxyguanosine, and urinary interleukin-2 levels were significantly lower [39]. These findings indicate that chronic bladder inflammation might also play a role in DV, resulting in increased sensory activity and hyperactivity in the urethral sphincter. Future studies must focus on the interaction between urinary bladder and urethral sphincter activity, and the treatment should involve both dysfunctions.
This study has several limitations. First, the EP study technique may have some errors due to inexperienced hands. In this study, the absence of BCR was observed in a high percentage of patients with DV and some controls. Second, this study included women with stress urinary incontinence as controls. Although these women did not have voiding dysfunction, pudendal nerve injury due to multiple pregnancies and delivery might have resulted in abnormal EP results [40]. Furthermore, data on the recruitment of urethral sphincter EMG could not be assessed because the EP study was conducted before lower urinary tract surgery under intravenous general anesthesia. These confounding factors might have affected the results of this study. Nevertheless, the results showed that a high percentage of patients with DV had reinnervation or denervation of the urethral sphincter. Finally, the purpose of this study was to investigate the effect of neurological characteristics of DV on the therapeutic efficacy of BoNT-A injection. The data on therapeutic results of BoNT-A were not included in the results section. The electrophysiological condition of the urethral sphincter was not expected to change after the BoNT-A injection. Therefore, repeated examination was not performed after BoNT-A treatment. The findings of this study provide valuable insight into the pathophysiology of DV and can help determine the optimal treatment strategy.

5. Conclusions

This study showed that 62.5% of women with DV had urethral sphincter reinnervation or denervation. After repeated BoNT-A injections into the urethral sphincter, 47.9% of patients had satisfactory treatment outcomes. Furthermore, the results showed that higher voiding detrusor pressure and DV subtypes in VUDS were not predictors of treatment outcomes. Patients with DV, along with urethral reinnervation, were found to have improved cQmax after repeated urethral sphincter BoNT-A injections during follow-up.

Author Contributions

Conceptualization, H.-C.K. and T.-L.C.; methodology, T.-L.C., Y.-H.J. and H.-C.K.; software, Y.-H.J.; validation, H.-C.K.; formal analysis, T.-L.C.; investigation, T.-L.C.; data curation, Y.-H.J.; writing—original draft preparation, T.-L.C.; writing—review and editing, Y.-H.J. and H.-C.K.; visualization, H.-C.K.; supervision, H.-C.K.; project administration, H.-C.K. and T.-L.C.; funding acquisition, H.-C.K., T.-L.C. and Y.-H.J. All authors have read and agreed to the published version of the manuscript.

Funding

This study was founded by the Buddhist Tzu Chi Medical Foundation, grants TCMF-MP-110-03-01, TCMF-SP 112-01, and TCMF-IMC 112-01.

Institutional Review Board Statement

The study was conducted according to the guidelines of the Declaration of Helsinki and approved by the Institutional Review Board and Ethics Committee of Buddhist Tzu Chi General Hospital (IRB: 110-265-A).

Informed Consent Statement

Informed consent was obtained from all subjects involved in the study.

Data Availability Statement

The original contributions presented in the study are included in the article, further inquiries can be directed to the corresponding author.

Conflicts of Interest

The authors declare no conflicts of interest.

References

  1. Santis-Moya, F.; Calvo, C.I.; Rojas, T.; Dell’Oro, A.; Baquedano, P.; Saavedra, A. Urodynamic and clinical features in women with overactive bladder: When to suspect concomitant voiding dysfunction? Neurourol. Urodyn. 2021, 40, 1509–1514. [Google Scholar] [CrossRef]
  2. Carlson, K.V.; Rome, S.; Nitti, V.W. Dysfunctional voiding in women. J. Urol. 2001, 165, 143–148. [Google Scholar] [CrossRef] [PubMed]
  3. Hsiao, S.M.; Lin, H.H.; Kuo, H.C. Videourodynamic Studies of Women with Voiding Dysfunction. Sci. Rep. 2017, 7, 6845. [Google Scholar] [CrossRef] [PubMed]
  4. Morin, F.; Akhavizadegan, H.; Kavanagh, A.; Moore, K. Dysfunctional voiding: Challenges of disease transition from childhood to adulthood. Can. Urol. Assoc. J. 2018, 12 (Suppl. S1), S42–S47. [Google Scholar] [CrossRef]
  5. Minardi, D.; d’Anzeo, G.; Parri, G.; Polito, M.; Piergallina, M.; El Asmar, Z.; Marchetti, M.; Muzzonigro, G. The role of uroflowmetry biofeedback and biofeedback training of the pelvic floor muscles in the treatment of recurrent urinary tract infections in women with dysfunctional voiding: A randomized controlled prospective study. Urology 2010, 75, 1299–1304. [Google Scholar] [CrossRef] [PubMed]
  6. Amundsen, C.L.; Richter, H.E.; Menefee, S.A.; Komesu, Y.M.; Arya, L.A.; Gregory, W.T.; Myers, D.L.; Zyczynski, H.M.; Vasavada, S.; Nolen, T.L.; et al. OnabotulinumtoxinA vs Sacral Neuromodulation on Refractory Urgency Urinary Incontinence in Women: A Randomized Clinical Trial. JAMA 2016, 316, 1366–1374. [Google Scholar] [CrossRef] [PubMed]
  7. Zhao, Y.; Wang, D.; Zou, L.; Mao, L.; Yu, Y.; Zhang, T.; Bai, B.; Chen, Z. Comparison of the efficacy and safety of sacral root magnetic stimulationwith transcutaneous posterior tibial nerve stimulation in the treatment of neurogenic detrusor overactivity: An exploratory randomized controlled trial. Transl. Androl. Urol. 2022, 11, 821–831. [Google Scholar] [CrossRef] [PubMed]
  8. Souto, S.C.; Reis, L.O.; Palma, T.; Palma, P.; Denardi, F. Prospective and randomized comparison of electrical stimulation of the posterior tibial nerve versus oxybutynin versus their combination for treatment of women with overactive bladder syndrome. World J. Urol. 2014, 32, 179–184. [Google Scholar] [CrossRef]
  9. Seth, J.; Rintoul-Hoad, S.; Sahai, A. Urethral Sphincter Injection of Botulinum Toxin A: A Review of Its Application and Outcomes. Low. Urin. Tract. Symptoms 2018, 10, 109–115. [Google Scholar] [CrossRef]
  10. Jiang, Y.H.; Chen, S.F.; Jhang, J.F.; Kuo, H.C. Therapeutic effect of urethral sphincter onabotulinumtoxinA injection for urethral sphincter hyperactivity. Neurourol. Urodyn. 2018, 37, 2651–2657. [Google Scholar] [CrossRef] [PubMed]
  11. Gross, C.; Habli, M.; Lindsell, C.; South, M. Sacral neuromodulation for nonobstructive urinary retention: A meta-analysis. Female Pelvic Med. Reconstr. Surg. 2010, 16, 249–253. [Google Scholar] [CrossRef] [PubMed]
  12. Sinha, S.; Everaert, K.; Kheir, G.B.; Roberts, N.; Solomon, E.; Belal, M.; Selai, C.; Perrouin-Verbe, M.A.; Spicchiale, C.F.; Wein, A.; et al. Could a better understanding of the underlying pathophysiologies lead to more informed treatment choices in patients with lower urinary tract dysfunction due to an acontractile or underactive detrusor? ICI-RS 2023. Neurourol. Urodyn. 2023, 43, 1381–1390. [Google Scholar] [CrossRef] [PubMed]
  13. Doumouchtsis, S.K.; de Tayrac, R.; Lee, J.; Daly, O.; Melendez-Munoz, J.; Lindo, F.M.; Cross, A.; White, A.; Cichowski, S.; Falconi, G.; et al. An International Continence Society (ICS)/International Urogynecological Association (IUGA) joint report on the terminology for the assessment and management of obstetric pelvic floor disorders. Int. Urogynecol J. 2023, 34, 1–42. [Google Scholar] [CrossRef] [PubMed]
  14. Haylen, B.T.; de Ridder, D.; Freeman, R.M.; Swift, S.E.; Berghmans, B.; Lee, J.; Monga, A.; Petri, E.; Rizk, D.E.; Sand, P.K.; et al. An International Urogynecological Association (IUGA)/International Continence Society (ICS) joint report on the terminology for female pelvic floor dysfunction. Int. Urogynecol J. 2010, 21, 5–26. [Google Scholar] [CrossRef] [PubMed]
  15. Jiang, Y.H.; Kuo, H.C. High percentage of neurologic deficits in the electrophysiology study of the lower urinary tract in patients with detrusor underactivity and chronic urinary retention. Neurourol. Urodyn. 2021, 40, 883–890. [Google Scholar] [CrossRef] [PubMed]
  16. Blaivas, J.G. Sphincter electromyography. Neurourol. Urofyn 1983, 2, 269–288. [Google Scholar] [CrossRef]
  17. Yoshimura, N.; Ogawa, T.; Miyazato, M.; Kitta, T.; Furuta, A.; Chancellor, M.B.; Tyagi, P. Neural mechanisms underlying lower urinary tract dysfunction. Korean J. Urol. 2014, 55, 81–90. [Google Scholar] [CrossRef] [PubMed]
  18. Brostrom, S.; Jennum, P.; Lose, G. Motor evoked potentials from the striated urethral sphincter: A comparison of concentric needle and surface electrodes. Neurourol. Urodyn. 2003, 22, 123–129. [Google Scholar] [CrossRef] [PubMed]
  19. De Ridder, D.; Ost, D.; Bruyninckx, F. The presence of Fowler’s syndrome predicts successful long-term outcome of sacral nerve stimulation in women with urinary retention. Eur. Urol. 2007, 51, 229–233. [Google Scholar] [CrossRef]
  20. Amarenco, G.; Ismael, S.S.; Bayle, B.; Denys, P.; Kerdraon, J. Electrophysiological analysis of pudendal neuropathy following traction. Muscle Nerve 2001, 24, 116–119. [Google Scholar] [CrossRef]
  21. Fowler, C.J.; Kirby, R.S. Electromyography of urethral sphincter in women with urinary retention. Lancet 1986, 1, 1455–1457. [Google Scholar] [CrossRef] [PubMed]
  22. Fowler, C.J.; Christmas, T.J.; Chapple, C.R.; Parkhouse, H.F.; Kirby, R.S.; Jacobs, H.S. Abnormal electromyographic activity of the urethral sphincter, voiding dysfunction, and polycystic ovaries: A new syndrome? BMJ 1988, 297, 1436–1438. [Google Scholar] [CrossRef] [PubMed]
  23. Godec, C.J.; Esho, J.; Cass, A.S. Correlation among cystometry, urethral pressure profilometry and pelvic floor electromyography in the evaluation of female patients with voiding dysfunction symptoms. J. Urol. 1980, 124, 678–682. [Google Scholar] [CrossRef]
  24. Sakakibara, R.; Hattori, T.; Uchiyama, T.; Yamanishi, T.; Ito, H.; Ito, K. Neurogenic failures of the external urethral sphincter closure and relaxation: A videourodynamic study. Auton. Neurosci. 2001, 86, 208–215. [Google Scholar] [CrossRef]
  25. Everaert, K.; Van Laecke, E.; De Muynck, M.; Peeters, H.; Hoebeke, P. Urodynamic assessment of voiding dysfunction and dysfunctional voiding in girls and women. Int. Urogynecology J. Pelvic Floor Dysfunct. 2000, 11, 254–264. [Google Scholar] [CrossRef] [PubMed]
  26. Chen, Y.C.; Kuo, H.C. Clinical and video urodynamic characteristics of adult women with dysfunctional voiding. J. Formos. Med. Assoc. 2014, 113, 161–165. [Google Scholar] [CrossRef]
  27. Bauer, A. Dysfunctional voiding: Update on evaluation and treatment. Curr. Opin. Pediatr. 2021, 33, 235–242. [Google Scholar] [CrossRef] [PubMed]
  28. Ho, F.C.S.; He, C.; Yao, H.H.; O’Connell, H.E.; Gani, J. Efficacy of sacral neuromodulation and percutaneous tibial nerve stimulation in the treatment of chronic nonobstructive urinary retention: A systematic review. Neurourol. Urodyn. 2021, 40, 1078–1088. [Google Scholar] [CrossRef] [PubMed]
  29. Eldred-Evans, D.; Dasgupta, P. Use of botulinum toxin for voiding dysfunction. Transl. Androl. Urol. 2017, 6, 234–251. [Google Scholar] [CrossRef]
  30. Kuo, H.C. Botulinum A toxin urethral injection for the treatment of lower urinary tract dysfunction. J. Urol. 2003, 170, 1908–1912. [Google Scholar] [CrossRef]
  31. Nadeem, M.; Lindsay, J.; Pakzad, M.; Hamid, R.; Ockrim, J.; Greenwell, T. Botulinum toxin A injection to the external urethral sphincter for voiding dysfunction in females: A tertiary center experience. Neurourol. Urodyn. 2022, 41, 1793–1799. [Google Scholar] [CrossRef] [PubMed]
  32. Lin, Y.H.; Chiang, B.J.; Liao, C.H. Mechanism of Action of Botulinum Toxin A in Treatment of Functional Urological Disorders. Toxins 2020, 12, 129. [Google Scholar] [CrossRef]
  33. Smith, C.P.; Chancellor, M.B. Emerging role of botulinum toxin in the management of voiding dysfunction. J. Urol. 2004, 171 Pt 1, 2128–2137. [Google Scholar] [CrossRef] [PubMed]
  34. Lee, C.L.; Chen, S.F.; Jiang, Y.H.; Kuo, H.C. Effect of videourodynamic subtypes on treatment outcomes of female dysfunctional voiding. Int. Urogynecol J. 2022, 33, 1283–1291. [Google Scholar] [CrossRef] [PubMed]
  35. Chow, P.M.; Hsiao, S.M.; Kuo, H.C. Obstructive patterns in videourodynamic studies predict responses of female dysfunctional voiding treated with or without urethral botulinum toxin injection: A long-term follow-up study. Int. Urogynecol J. 2020, 31, 2557–2564. [Google Scholar] [CrossRef]
  36. Phelan, M.W.; Franks, M.; Somogyi, G.T.; Yokoyama, T.; Fraser, M.O.; Lavelle, J.P.; Yoshimura, N.; Chancellor, M.B. Botulinum toxin urethral sphincter injection to restore bladder emptying in men and women with voiding dysfunction. J. Urol. 2001, 165, 1107–1110. [Google Scholar] [CrossRef] [PubMed]
  37. Panicker, J.N.; Seth, J.H.; Khan, S.; Gonzales, G.; Haslam, C.; Kessler, T.M.; Fowler, C.J. Open-label study evaluating outpatient urethral sphincter injections of onabotulinumtoxinA to treat women with urinary retention due to a primary disorder of sphincter relaxation (Fowler’s syndrome). BJU Int. 2016, 117, 809–813. [Google Scholar] [CrossRef]
  38. Panicker, J.N.; Anding, R.; Arlandis, S.; Blok, B.; Dorrepaal, C.; Harding, C.; Marcelissen, T.; Rademakers, K.; Abrams, P.; Apostolidis, A. Do we understand voiding dysfunction in women? Current understanding and future perspectives: ICI-RS 2017. Neurourol. Urodyn. 2018, 37 (Suppl. S4), S75–S85. [Google Scholar] [CrossRef]
  39. Yu, W.R.; Jiang, Y.H.; Jhang, J.F.; Kuo, H.C. Urine biomarker could be a useful tool for differential diagnosis of a lower urinary tract dysfunction. Tzu Chi Med. J. 2023, 36, 110–119. [Google Scholar] [CrossRef]
  40. Smith, A.R.; Hosker, G.L.; Warrell, D.W. The role of pudendal nerve damage in the aetiology of genuine stress incontinence in women. BJOG Int. J. Obstet. Gynaecol. 1989, 96, 29–32. [Google Scholar] [CrossRef]
Biomedicines 12 01902 g001
Figure 1. Different electromyographic findings in patients with dysfunctional voiding. (A) Positive sharp waves and the presence of fibrillation indicating denervation changes. (B) Polyphasic motor-unit action potential indicating reinnervation changes. (C) Normal motor unit action potentials. X-labeling: time (millisecond), Y-labeling: Voltage, Div: Digital input group voltage.
Figure 1. Different electromyographic findings in patients with dysfunctional voiding. (A) Positive sharp waves and the presence of fibrillation indicating denervation changes. (B) Polyphasic motor-unit action potential indicating reinnervation changes. (C) Normal motor unit action potentials. X-labeling: time (millisecond), Y-labeling: Voltage, Div: Digital input group voltage.
Biomedicines 12 01902 g001
Table 1. Demographic and VUDS findings of patients with dysfunctional voiding (n = 48).
Table 1. Demographic and VUDS findings of patients with dysfunctional voiding (n = 48).
Age (Years)55.2 ± 16.1
Comorbidity
  Diabetes mellitus7 (14.6%)
  Hypertension14 (29.2%)
  Coronary artery disease3 (6.3%)
  Chronic kidney disease2 (4.2%)
  Recurrent urinary tract infection7 (14.6%)
Previous surgery
  Transurethral incision of the bladder neck7 (14.6%)
  Hysterectomy10 (20.8%)
  Spinal surgery4 (8.3%)
Videourodynamic study
  Detrusor overactivity38 (79.2%)
  Detrusor underactivity1 (2.1%)
  Vesicoureteral reflux2 (4.2%)
Table 2. VUDS parameters and EP study data between patients with DV and controls.
Table 2. VUDS parameters and EP study data between patients with DV and controls.
DV (n = 48) Control (n = 16) p-Value
Age (years) 55.2 ± 16.1 61.1 ± 14.7 0.184
VUDS parameters
  Qmax (mL/s) 9.3 ± 5.4 10.1 ± 15.0 0.520
  Volume (mL) 174.3 ± 93.5 159.6 ± 202.7 0.950
  PVR (mL) 156.5 ± 191.7 159.5 ± 198.1 0.960
  CBC (mL) 310.7 ± 184.8 319.1 ± 194.5 0.883
  cQmax 0.63 ± 0.42 0.65 ± 0.68 0.944
  VE 0.57 ± 0.36 0.55 ± 0.46 0.842
  Pdet (cmH2O) 50.9 ± 26.3 20.5 ± 18.0 0.001
  BCI 96.0 ± 32.7 74.1 ± 74.8 0.263
EP parameters
  BCR latency time (ms) 1.78 ± 2.13 1.00 ± 1.41 0.185
  Absence of BCR 19 (39.6%) 2 (12.5%) 0.092
  L’t NCV (ms) 1.50 ± 1.57 1.05 ± 1.20 0.340
  R’t NCV (ms) 2.03 ± 2.19 1.81 ± 1.84 0.548
  Latency < 2.5 ms 33 (68.8%) 11 (68.8%) 0.396
  L’t NCV amp. (mV) 2.19 ± 6.26 2.44 ± 4.07 0.881
  R’t NCV amp. (mV) 1.32 ± 2.51 2.23 ± 5.32 0.393
  Decreased amplitude 36 (75.0%) 9 (56.2%) 0.140
EMG
  Denervation2 (4.2%) 0 (0.0%) 0.436
  Reinnervation28 (58.3%) 3 (18.8%) 0.001
  Normal EMG18 (37.5%)13 (71.2%)0.024
DV: dysfunctional voiding; Qmax: maximum flow rate; PVR: post-void residual volume; CBC: cystometric bladder capacity; cQmax: correct maximum flow rate (defined as Qmax/Volume1/2); VE: voiding efficiency; Pdet: voiding detrusor pressure at maximum urinary flow rate; BCI: bladder contractility index; EP: electrophysiological study; BCR: bulbocavernous reflex; NCV: nerve conduction velocity, amp: amplitude, EMG: electromyography.
Table 3. Baseline videourodynamic and electrophysiological study parameters between patients of dysfunctional voiding with or without reinnervation of the urethral sphincter.
Table 3. Baseline videourodynamic and electrophysiological study parameters between patients of dysfunctional voiding with or without reinnervation of the urethral sphincter.
DV with ReIN
(n = 28) 		DV without ReIN
(n = 20) 		p-Value
Age (years) 56.7 ± 15.3 53.4 ± 17.9 0.528
VUDS parameters
  Qmax (mL/s) 9.3 ± 5.4 9.4 ± 6.1 0.981
  Volume (mL) 164.7 ± 78.5 164.2 ± 90.8 0.983
  PVR (mL) 81.0 ± 163.4 137.2 ± 177.6 0.293
  CBC (mL) 239.8 ± 180.2 301.4 ± 158.9 0.262
  cQmax 0.68 ± 0.45 0.61 ± 0.41 0.606
  VE 0.79 ± 0.27 0.67 ± 0.37 0.252
  Pdet (cmH2O) 49.3 ± 26.1 47.9 ± 23.4 0.859
  BCI 94.3 ± 36.5 94.8 ± 22.9 0.964
EP parameters
  BCR latency (ms)1.60 ± 1.53 2.57 ± 2.93 0.279
  Absent BCR 12 (42.9%) 10 (50.0%) 0.444
  L’t NCV latency (ms) 1.85 ± 1.87 1.07 ± 0.70 0.128
  R’t NCV latency (ms) 2.03 ± 1.62 2.24 ± 3.16 0.765
  Latency < 2.5 ms 14 (50.0%) 8 (40.0%) 0.745
  L’t NCV amp. (mV) 1.96 ± 7.08 1.43 ± 2.42 0.782
  R’t NCV amp. (mV) 0.75 ± 1.66 1.12 ± 1.49 0.480
  Decreased amplitude 25 (89.3%) 14 (70.0%) 0.647
DV: dysfunctional voiding; ReIN: reinnervation; Qmax: maximum flow rate; PVR: post-void residual volume; CBC: cystometric bladder capacity; cQmax: correct maximum flow rate (defined as Qmax/Volume1/2); VE: voiding efficiency; Pdet: voiding detrusor pressure at maximum urinary flow rate; BCI: bladder contractility index; BCR: bulbocavernous reflex; NCV: nerve conduction velocity.
Table 4. Comparison of postoperative cQmax between patients with DV with or without reinnervation or denervation and GRA.
Table 4. Comparison of postoperative cQmax between patients with DV with or without reinnervation or denervation and GRA.
DV with ReIN
(n = 28) 		DV without ReIN
(n = 20) 		p-Value
Pre-OP 0.73 ± 0.44 0.60 ± 0.38 0.733
Post-OP 1M 1.10 ± 0.68 * 0.70 ± 0.41 0.298
Post-OP 3M 1.03 ± 0.56 * 0.61 ± 0.30 0.314
Post-OP 6M 0.77 ± 0.32 0.55 ± 0.68 0.481
Post-OP 9M 0.61 ± 0.78 0.43 ± 0.51 0.308
GRA at 1 month1.98 ± 1.44 1.77 ± 0.23 0.834
GRA at 3 months1.69 ± 0.64 1.66 ± 1.48 0.733
GRA at 6 months1.34 ± 1.89 1.03 ± 2.67 0.246
GRA at 9 months1.19 ± 1.02 1.36 ± 0.92 0.641
GRA: global response assessment; DV: dysfunctional voiding; cQmax: correct maximum flow rate (defined as Qmax/Volume1/2); ReIN: reinnervation; * Significant difference compared with pre-op data (p < 0.05).
Table 5. Baseline VUDS and EP parameters of patients with DV with GRA ≥ 2 and GRA < 2 after urethral sphincter BoNT-A injections.
Table 5. Baseline VUDS and EP parameters of patients with DV with GRA ≥ 2 and GRA < 2 after urethral sphincter BoNT-A injections.
GRA ≥ 2 (n = 23)GRA < 2 (n = 25)p-Value
Age (years) 56.9 ± 18.0 65.2 ± 19.8 0.457
VUDS parameters
  Qmax (mL/s) 7.7 ± 3.9 8.7 ± 5.9 0.600
  Volume (mL) 150.8 ± 83.1 169.8 ± 121.1 0.599
  PVR (mL) 158.8 ± 196.3 155.0 ± 192.8 0.953
  CBC (mL) 300.1 ± 167.9 317.8 ± 198.5 0.772
  cQmax 0.62 ± 0.32 0.68 ± 0.37 0.729
  VE 0.58 ± 0.33 0.57 ± 0.38 0.972
  Pdet (cmH2O) 57.5 ± 38.0 50.8 ± 28.8 0.539
  BCI 100.0 ± 39.6 88.0 ± 46.1 0.410
EP parameters
  BCR latency (ms) 1.50 ± 2.87 2.13 ± 1.90 0.493
  BCR < 33 ms 10 (43.5%) 16 (64.0%) 0.500
  L’t NCV latency (ms) 1.28 ± 1.13 1.64 ± 1.98 0.511
  R’t NCV latency (ms) 1.88 ± 1.65 2.45 ± 2.82 0.477
  Latency < 2.5 ms 9 (39.1%) 13(52.0%) 1.000
  L’t NCV amp. (mV) 3.24 ± 8.08 0.74 ± 1.22 0.228
  R’t NCV amp. (mV) 1.85 ± 3.09 0.60 ± 1.05 0.089
  Amplitude > 1 mV 4 (17.4%) 6 (24.0%) 0.706
  Reinnervation EMG13 (56.5%) 15 (60.0%) 0.503
Dysuria VAS
at 1 month3.83 ± 1.58 *4.18 ± 2.94 *0.234
at 3 months3.34 ± 2.49 *2.98 ± 2.88 *0.568
at 6 months2.47 ± 1.83 *2.58 ± 2.67 *0.417
at 9 months2.52 ± 2.54 *2.77 ± 2.33 *0.453
GRA: global response assessment; DV: dysfunctional voiding; Qmax: maximum flow rate; PVR: post-void residual volume; CBC: cystometric bladder capacity; cQmax: correct maximum flow rate (defined as Qmax/Volume1/2); VE: voiding efficiency; Pdet: voiding detrusor pressure at maximum urinary flow rate; BCI: bladder contractility index; BCR: bulbocavernosus reflex; NCV: nerve conduction velocity; VAS: visual analog scale; * Significant difference compared with pre-op data (p < 0.05).
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Chang, T.-L.; Jiang, Y.-H.; Kuo, H.-C. Impact of Urethral Sphincter Electrophysiology on Botulinum Toxin A Treatment in Women with Non-Neurogenic Dysfunctional Voiding. Biomedicines 2024, 12, 1902. https://doi.org/10.3390/biomedicines12081902

AMA Style

Chang T-L, Jiang Y-H, Kuo H-C. Impact of Urethral Sphincter Electrophysiology on Botulinum Toxin A Treatment in Women with Non-Neurogenic Dysfunctional Voiding. Biomedicines. 2024; 12(8):1902. https://doi.org/10.3390/biomedicines12081902

Chicago/Turabian Style

Chang, Tien-Lin, Yuan-Hong Jiang, and Hann-Chorng Kuo. 2024. "Impact of Urethral Sphincter Electrophysiology on Botulinum Toxin A Treatment in Women with Non-Neurogenic Dysfunctional Voiding" Biomedicines 12, no. 8: 1902. https://doi.org/10.3390/biomedicines12081902

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop